Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report to announce the completion of its acquisition of DuPont's pharmaceutical business on October 1, 2001. This significant transaction involved a cash payment of approximately $7.8 billion to DuPont, funded through a combination of long-term debt, commercial paper, and internal resources. The acquisition encompasses DuPont Pharmaceuticals Company and its subsidiaries, which are engaged in the research, development, manufacturing, and marketing of pharmaceutical products. This strategic move is expected to bolster BMY's position in the pharmaceutical market and expand its product pipeline. Investors should note that financial statements and pro forma information related to this acquisition have been previously reported in earlier 8-K/A filings.
Key Highlights
- 1Bristol-Myers Squibb completed the acquisition of DuPont's pharmaceutical business on October 1, 2001.
- 2The purchase price for DuPont's pharmaceutical assets was approximately $7.8 billion in cash.
- 3The acquisition was funded through a mix of long-term debt, commercial paper facilities, and internal funds.
- 4The acquired business includes entities involved in the research, development, manufacturing, and marketing of pharmaceutical products.
- 5An amendment to the original Purchase Agreement dated October 1, 2001, is referenced.
- 6A press release dated October 2, 2001, announcing the completion of the acquisition is attached as an exhibit.